Biodesix (BDSX) revenue breakdown
By product, Diagnostic Tests is the largest at 89% of fiscal 2025 revenue, growing 29% a year over 6 years.
Revenue by product
Fiscal years, as Biodesix reports them in its 10-K filings; fiscal 2025 total $88M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Tests | $17M | $41M | $49M | $35M | $45M | $65M | $79M | 89% |
| Development Services | $7M | $5M | $6M | $4M | $4M | $7M | $9M | 11% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BDSX.
Open BDSX in InvestinglyQuestions
Where does Biodesix make its money?
In fiscal 2025, by product: Diagnostic Tests $79M, Development Services $9M.
From Biodesix's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.